19 Jul 2019

Transparency notification BlackRock, Inc.

Read More
9 Jul 2019

Transparency notification BlackRock, Inc.

Read More
1 Jul 2019

Transparency notifications BlackRock, Inc.

Read More
27 Jun 2019

UCB and Amgen Provide Regulatory Update on Status of EVENITY® (romosozumab) in the EU

Read More
24 Jun 2019

Transparency notifications BlackRock, Inc.

Read More
13 Jun 2019

UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

Read More
12 Jun 2019

Transparency notifications BlackRock, Inc.

Read More
6 Jun 2019

UCB Showcases the Depth of its Immunology Research and Commitment to Patients at EULAR 2019

Read More
19 May 2019

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

Read More
2 May 2019

Transparency notifications BlackRock, Inc.

Read More
Subscribe to